NTLA Intellia Therapeutics, Inc.
NTLA Intellia Therapeutics, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 bear converging
POC $12.93 · VWAP $12.70 · -11.7% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
4 watchlists
NTLA Price Structure
Loading timeframes…
Peers
Every watchlist NTLA belongs to, members best 30-day change first — NTLA highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
@ibb
@biotech-scan
@insider-universe
Reported the quarter ending 2026-06-30: revenue $8M, diluted EPS -$0.80, net income -$107M (SEC filing). Across the print the stock moved +8.8% (close before → first close after).
full note →Against street estimates
How NTLA's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
News (last pull)
Headlines about NTLA from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 31 days ago · Sep 22
- Intellia Therapeutics (NTLA) Stock Price & Overview
- Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics
- NTLA Q2 2026 Earnings Report on 8/6/2026 - MarketBeat
- Intellia Therapeutics Inc (NTLA) Earnings Date & Report ...
- Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Sagimet Biosciences, Inc. Class A (SGMT) | Markets Insider
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
NTLA research tape
112 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to NTLA.
NTLA — watch above $18.50